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lead TAVs to become non-circular, which could affect long-term durability, although the real impact is not known. 14 
Endocarditis
Infective endocarditis has been reported to occur in 0.5-3.4% of cases after TAVI and 1-6% after surgical aortic valve replacement (SAVR). 13, 15 The predominant agents reported to have caused prosthetic valve endocarditis were Staphylococci (31.5%), Enterococci (20%) and Streptococci (14%), based on 29 certain cases of endocarditis from about 4000 TAVI patients of a multicenter registry. 15 Diagnosis of TAV endocarditis can be difficult as older patients may present with subtle and atypical symptoms. 16 Endocarditis is shown with echocardiography as mobile vegetations, aortic root abscess formation, or progressive stenosis/regurgitation (due to prosthetic valve dehiscence). Intraprosthetic regurgitation occurring late after TAVI is suggestive of infective endocarditis, particularly when it is not associated with valve stenosis. 13 
Bioprosthesis Thrombosis
Bioprosthesis thrombosis has been reported in two different forms.
First, as a symptomatic obstructive valve thrombosis, resulting in an increase in the transvalvular gradient and reduction in the effective orifice area measured by echocardiography, which is a rare event and reported in about 0.5% of TAVI patients. 13, 17 Second, as asymptomatic subclinical valve thrombosis causing thickening and reduced leaflet motion of bioprosthetic aortic valves detected by CT scan with normal transvalvular gradients at transthoracic ECG. This form is reported to be more frequent in patients treated percutaneously, ranging from 5% to 40% of TAVI patients. 18 The incomplete expansion of a TAV's stent as well as its metallic nature seem to be two of the main factors increasing the risk of subclinical thrombosis. 
Definitions and Diagnosis of Structural Valve Degeneration
SVD in bioprosthesis has been poorly defined for a long time.
Traditionally, it is considered an acquired intrinsic bioprosthetic valve abnormality characterised by the deterioration of the leaflets or supporting structures. One of the causes of SVD is the mechanical stress and the abnormal flow at the surface of the leaflet, which leads to tissue disruption or thickening, collagen fibre disruption and tissue calcification, but the precise mechanism is not known. Risk factors often associated with bioprosthetic SVD are younger age, mitral valve position, end-stage renal disease, higher calcium-phosphorus product, hyperparathyroidism, hypertension and pregnancy. [19] [20] [21] [22] Other clinical valve abnormalities that do not cause deterioration of valve tissue, are not included in the definition of SVD. These include patient-prosthesis mismatch, device malposition, paravalvular regurgitation and abnormal frame expansion in the case of selfexpanding transcatheter bioprostheses. 10, 13, 22 Prosthetic valve thrombosis and infective endocarditis are not included in the definition of SVD, but these complications may subsequently lead to SVD, even if treated successfully. 17, 23, 24 The lack of standard definitions for bioprosthesis dysfunction have affected the possibility of a proper comparison of durability studies.
Most studies regarding surgical prosthesis have associated SVD with the need for reoperation, but did not provide any specific criteria to define SVD and/or the indication for reoperation. Furthermore, reoperation does not necessary imply presence of SVD as well as SVD does not always lead to reoperation, and older patients are often refused redo surgery because of their high or prohibitive surgical risk profile and their frailty. 25 With the worldwide increase in TAVI long-term durability. 26 The taskforce characterised structural valve dysfunction as 'haemodynamic SVD' and/or 'morphological SVD'.
Haemodynamic SVD is defined as the presence of permanent changes in valve function assessed by echocardiography, even without evidence of morphological SVD. There are two different degrees of haemodynamic SVD. Moderate is defined by the presence of a mean gradient 
≥20 mmHg and <40 mmHg and/or ≥10 mmHg and <20 mmHg change from gradient at baseline (valuated before discharge or within 30 days of valve implantation) and/or the onset of moderate, new or worsening (>1+/4+) of intra-prosthetic valve regurgitation; severe, with mean gradient ≥40 mmHg and/or ≥20 mmHg change from baseline and/or severe, new or worsening (>2+/4+) intra-prosthetic aortic regurgitation.
Morphological SVD includes abnormalities in leaflet integrity, structure, function and strut/frame. The diagnosis is based on imaging or autopsy findings. BVF definition integrates severe haemodynamic SVD and its clinical consequences. It is important to stress that BVF could be a consequence of pathophysiological processes unrelated to SVD, such as thrombosis, endocarditis or non-structural valve dysfunction.
BVF includes any of the following ( Table 2 ):
• Bioprosthetic valve dysfunction at autopsy, very likely related to the cause of death, or 'valve-related death', defined as any death caused by bioprosthetic valve dysfunction in the absence of confirmatory autopsy.
• Aortic valve reintervention (i.e. valve-in-valve TAVI, paravalvular leak closure or SAVR).
• Severe hemodynamic SVD. 
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with anticoagulation, because these leaflets might still be prone Table 2) .
Bioprostheses Durability Data
Long-term durability is one of the main limitations of surgical a rate of freedom from SVD of 48.5%. 34, 35 Unfortunately, the lack of standard definitions for valve dysfunction affects any comparison between different studies ( Table 3) .
It is well known that transcatheter aortic valves can degenerate in a manner similar to surgical bioprostheses, but durability of TAVs could be shorter than their surgical counterpart because of the possible trauma that can occur during initial valve preparation and compression, balloon dilatation or as a suboptimal leaflet coaptation, leaflet folding or leaflet-frame contact due to asymmetrical frame expansion. Reports from national registries confirm low rates of TAV dysfunction at long-term follow-up. Data from the French Aortic National
CoreValve and Edwards (FRANCE-2) registry showed an incidence of severe and moderate/severe SVD of 2.5% and 13.3%, respectively, in surviving patients at 5 years from the procedure, while Blackman et al. reported an incidence of severe and moderate SVD of 0.4% and 8.7% respectively up to 10 years in the UK TAVI Registry. 43, 44 Finally, a recent analysis from the Nordic Aortic Valve Intervention (NOTION) trial reported lower rates of moderate-to-severe SVD after TAVI compared with surgery (24% versus 4.8% for TAVI and SAVR respectively), whereas there was no difference in terms of BVF (6.7% versus 7.5% for TAVI and SAVR respectively). Intraprosthetic regurgitation occurring late after TAVI suggests infective endocarditis, particularly when not associated with stenosis. 13 In this case, targeted antibiotic therapy represents the first line of treatment. In patients presenting with severe aortic regurgitation, transcatheter heart valve retrieval and SAVR should be considered. Redo TAVI is an alternative in those patients in which infection has been controlled and blood cultures are negative. Vitamin K antagonists are the most used anticoagulants but novel oral anticoagulation therapy has also been shown to be effective. Redo TAVI is another option in the management of TAV failure. This strategy has been demonstrated to be safe and it is associated with favourable clinical and echocardiographic outcomes. 47 When a balloonexpandable TAV fails, implantation of a second same-sized balloonexpandable TAV is the most commonly used approach. 47 On the other hand, a supra-annular TAV may be preferable in cases of small native annulus due to the possibility of a high residual transvalvular gradient.
Redo TAVI strategy has several advantages:
• It is safe, with lower risk of periprocedural complications compared with redo SAVR, which is technically challenging and carries a higher risk of mortality and morbidity than the first valve procedure. 
Conclusion
With the expansion of TAVI indication to younger, lower-risk patients, data on long-term TAV durability are essential. The first studies reporting on SVD up to eight years after TAVI showed very low rates of TAV degeneration, comparing favourably with its surgical counterpart. The release of standardised definitions of SVD represents a fundamental step in allowing data comparison from different centres, with the aim of obtaining a better insight into its real incidence. Evidence suggests that redo TAVI seems to be a feasible and safer alternative to surgery for treatment of bioprostheses failure.
